Erasca Announces Positive Preliminary Phase 1 Data for Pan-RAS Molecular Glue ERAS-0015

Erasca (NASDAQ:ERAS) reported positive preliminary results from the Phase 1 trial of its pan-RAS molecular glue, ERAS-0015. The therapy showed a high response rate in non-small cell lung cancer and pancreatic cancer patients, with favorable tolerability and pharmacokinetic data.

By Maham Fatima Tue, May 5, 2026 at 8:04 PM GMT+3 2 min read · Yahoo Finance · May 5, 2026, 17:04 UTC

Tickers: $ERAS

Topics: biotech oncology RAS-targeting therapy

Read the full article at Yahoo Finance

More World news

Thomson Reuters Executives to Present at TD Securities Technology Conference PR Newswire · November 12, 2026, 16:00 UTC
BHP to Restructure Australian Iron Ore Operations Amid Rising Costs Seeking Alpha · November 12, 2026, 15:59 UTC
Capri Investment Group and GRIT Chicago Unveil $10 Billion Bronzeville Lakefront Development Plan PR Newswire · November 12, 2026, 16:00 UTC
Whoop Launches 'Whoop Humans' Social Network to Enhance Health Data Sharing TechCrunch · November 12, 2026, 16:00 UTC
SchoolWise Partners Advises on Sale of Wyalusing Valley and Wysox Children's Centers PR Newswire · November 12, 2026, 15:57 UTC
Jensen Huang Resigns as Nvidia CEO Amid Personal Scandal and Leadership Crisis CNBC · November 12, 2026, 15:45 UTC
Keurig Dr Pepper Launches $2 Billion Equity Offering to Reduce Debt Ahead of Corporate Split Seeking Alpha · November 12, 2026, 15:51 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC
Old National Bancorp Announces Quarterly Dividend of $0.4375 per Share Seeking Alpha · November 12, 2026, 15:53 UTC
Oman Investment Authority Signs Multi-Billion Dollar Investment Package with Chinese Partners PR Newswire · November 12, 2026, 15:52 UTC